Comparative Effectiveness and Safety of Infliximab and Adalimumab in Inflammatory Bowel Diseases: A Nationwide Danish Cohort Study

被引：0
|
作者：
Singh, Siddharth [1 ]
Andersen, Nynne Nyboe [2 ]
Andersson, Mikael [3 ]
Loftus, Edward V., Jr. [4 ]
Jess, Tine [5 ]
机构：
[1] Univ Calif San Diego, San Diego, CA 92103 USA
[2] Overgaden Neden Vandet 49a, Copenhagen, Denmark
[3] Statens Serum Inst, Copenhagen, Denmark
[4] Mayo Clin, Coll Med, Rochester, MN USA
[5] Bispebjerg Frederiksberg Hosp, Inst Prevent Med, Frederiksberg, Denmark
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2016年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
568
引用
收藏
页码：S260 / S260
页数：1
相关论文
共 50 条
  • [1] Comparative Effectiveness and Safety of Infliximab and Adalimumab in Inflammatory Bowel Diseases: A Nationwide Danish Cohort Study
    不详
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S260 - S260
  • [2] Comparative Effectiveness and Safety of Infliximab and Adalimumab in Inflammatory Bowel Diseases: A Nationwide Danish Cohort Study
    Singh, Siddharth
    Andersen, Nynne Nyboe
    Andersson, Mikael
    Loftus, Edward V., Jr.
    Jess, Tine
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S260 - S260
  • [3] Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice
    Tursi, A.
    Elisei, W.
    Brandimarte, G.
    Giorgetti, G.
    Penna, A.
    Castrignano, V.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2010, 14 (01) : 47 - 55
  • [4] Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis
    Han Wang
    Yue Hu
    Fang Chen
    Mengdie Shen
    BMC Pregnancy and Childbirth, 22
  • [5] Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis
    Wang, Han
    Hu, Yue
    Chen, Fang
    Shen, Mengdie
    BMC PREGNANCY AND CHILDBIRTH, 2022, 22 (01)
  • [6] Effectiveness and safety of switching from original infliximab to GP1111 biosimilar in inflammatory bowel diseases - prospective, cohort study
    Resal, T.
    Bacsur, P.
    Papista, M.
    Kata, D.
    Farkas, B.
    Balint, A.
    Fabian, A.
    Bor, R.
    Szepes, Z.
    Farkas, K.
    Molnar, T.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1696 - I1697
  • [7] Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
    Kamal, Mahmoud E.
    Werida, Rehab H.
    Radwan, Mahasen A.
    Askar, Safaa R.
    Omran, Gamal A.
    El-Mohamdy, Marwa A.
    Hagag, Radwa S.
    INFLAMMOPHARMACOLOGY, 2024, 32 (05) : 3259 - 3269
  • [8] Risk of acute arterial events associated with treatment of inflammatory bowel diseases: a nationwide Danish cohort study
    Ward, Daniel
    Andersson, Mikael
    Nyboe Andersen, Nynne
    Allin, Kristine Hojgaard
    Beaugerie, Laurent
    Jess, Tine
    Kirchgesner, Julien
    GUT, 2022, 71 (11) : 2373 - 2374
  • [9] Inflammatory Bowel Diseases and Prior Malignant Diagnoses - A Danish Nationwide Cohort Study 1996-2022
    Plovgaard, J.
    Wewer, M. Damsgaard
    Bendtsen, F.
    Burisch, J.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i2218 - i2219
  • [10] Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study
    Kamat, Nagesh
    Kedia, Saurabh
    Ghoshal, Uday C.
    Nehra, Abhimanyu
    Makharia, Govind
    Sood, Ajit
    Midha, Vandana
    Gupta, Varun
    Choudhuri, Gourdas
    Ahuja, Vineet
    INDIAN JOURNAL OF GASTROENTEROLOGY, 2019, 38 (01) : 44 - 54
12345